Literature DB >> 17853384

Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity.

Mario Hasler1, Richardus Vonk, Ludwig A Hothorn.   

Abstract

In this paper, we describe an adjusted method to facilitate non-inferiority tests in a three-arm design. While the methodology is readily available in the situation of homogeneous group variances, the adjusted method will also maintain the alpha-level in the presence of heteroscedasticity. We propose explicit criteria for an optimal allocation. Depending on the pattern of heterogeneity, remarkably unbalanced designs are power optimal. We will apply the method to a randomized clinical trial and a toxicological experiment. 2007 John Wiley & Sons, Ltd

Mesh:

Substances:

Year:  2008        PMID: 17853384     DOI: 10.1002/sim.3052

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Group-sequential three-arm noninferiority clinical trial designs.

Authors:  Toshimitsu Ochiai; Toshimitsu Hamasaki; Scott R Evans; Koko Asakura; Yuko Ohno
Journal:  J Biopharm Stat       Date:  2016-02-18       Impact factor: 1.051

2.  Social network targeting to maximise population behaviour change: a cluster randomised controlled trial.

Authors:  David A Kim; Alison R Hwong; Derek Stafford; D Alex Hughes; A James O'Malley; James H Fowler; Nicholas A Christakis
Journal:  Lancet       Date:  2015-05-04       Impact factor: 79.321

3.  Host-pathogen interactome mapping for HTLV-1 and -2 retroviruses.

Authors:  Nicolas Simonis; Jean-François Rual; Irma Lemmens; Mathieu Boxus; Tomoko Hirozane-Kishikawa; Jean-Stéphane Gatot; Amélie Dricot; Tong Hao; Didier Vertommen; Sébastien Legros; Sarah Daakour; Niels Klitgord; Maud Martin; Jean-François Willaert; Franck Dequiedt; Vincent Navratil; Michael E Cusick; Arsène Burny; Carine Van Lint; David E Hill; Jan Tavernier; Richard Kettmann; Marc Vidal; Jean-Claude Twizere
Journal:  Retrovirology       Date:  2012-03-29       Impact factor: 4.602

4.  Testing non-inferiority of a new treatment in three-arm clinical trials with binary endpoints.

Authors:  Nian-Sheng Tang; Bin Yu; Man-Lai Tang
Journal:  BMC Med Res Methodol       Date:  2014-12-18       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.